Clinical trials
Dilated Cardiomyopathy (DCM) clinical trials
Below are recruiting dilated cardiomyopathy (dcm) clinical trials, each written for real people, not researchers. We’re tracking 29 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07426419RecruitingPhase 1/Phase 2
Gene therapy for BAG3-related dilated cardiomyopathy
This trial tests a gene therapy (AFTX-201) for people with dilated cardiomyopathy caused by a BAG3 gene mutation. The therapy aims to improve heart function, and the study will check if it is safe and effective.
Miami, FloridaAges 18–70 - NCT07420907Recruiting
Tracking heart health over time
This study uses a wearable patch to monitor heart-related signs in people with heart conditions. It aims to learn more about how these conditions progress, which could help improve future care.
Chicago, IllinoisAges 18 years+ - NCT06902896RecruitingPhase 1/Phase 2
FAP iCDC therapy for advanced heart failure from dilated cardiomyopathy
This trial tests a new treatment called FAP iCDC for people with end-stage dilated cardiomyopathy, a type of heart muscle disease. It aims to see if this therapy is safe and helps improve heart function when standard medicines are no longer enough.
Hangzhou, ZhejiangAges 18–75 - NCT04265040Recruiting
Heart muscle disease registry for non-ischemic conditions
This trial is a registry, meaning it collects health information to help doctors study heart muscle diseases and plan future cardiovascular studies. You may be able to join if you have a non-ischemic cardiomyopathy such as dilated cardiomyopathy, certain forms of thick heart muscle, non-compaction, or arrhythmogenic right-sided disease.
Heidelberg, Baden-WurttembergAges 18–80 - NCT06464588RecruitingPhase 1
Testing safety of newborn stem cells for dilated cardiomyopathy in young adults and children
This study tests whether a single intravenous infusion of stem cells from donated newborn tissue is safe for people aged 4 to 39 with dilated cardiomyopathy (a weakened, enlarged heart). It aims to find a new option for those who haven't improved enough with standard heart failure medications.
Atlanta, GeorgiaAges 4–40 - NCT06607471Recruiting
Study on non-ischemic heart muscle diseases
This study looks at different types of heart muscle diseases that are not caused by blocked arteries (non-ischemic cardiomyopathies). It aims to better understand how to diagnose, predict outcomes, and treat these conditions by gathering information from many patients over time.
Milan, MilanoAges 18 years+ - NCT06688396Recruiting
Finding early signs of dilated cardiomyopathy with AI and mobile screening
This trial uses a smartphone app to screen first-degree relatives of people with dilated cardiomyopathy (DCM) for early signs of the condition. It aims to detect heart muscle weakness before symptoms start, so that treatment can begin sooner.
Lancaster, PennsylvaniaAges 18 years+ - NCT06741995Recruiting
Testing antibodies to predict heart muscle disease progression
This study looks at whether certain antibodies (proteins in your blood) can help predict how dilated cardiomyopathy will progress. By testing your blood, researchers hope to learn more about your condition and find better ways to manage it.
Wuhan, HubeiAges 18–75 - NCT06922851Recruiting
Protein filter therapy for dilated cardiomyopathy
This trial tests a protein filtering treatment (immunoadsorption) for people with dilated cardiomyopathy who have a specific antibody linked to heart damage. It aims to see if removing these antibodies can improve heart function.
Wuhan, HubeiAges 18–75 - NCT07137338RecruitingPhase 1
Gene therapy for BAG3-related dilated cardiomyopathy
This trial tests a one-time gene therapy called RP-A701 for people with dilated cardiomyopathy caused by a BAG3 gene mutation. The goal is to see if it is safe and can improve heart function.
San Diego, CaliforniaAges 18–65 - NCT07145138Recruiting
Multi-ethnic dilated cardiomyopathy registry
This study is a registry for people with dilated cardiomyopathy (DCM)—a condition where the heart's main pumping chamber becomes enlarged and weak. It aims to learn more about DCM, especially in people from different ethnic backgrounds, by collecting health information over time.
Chicago, IllinoisAges 18 years+ - NCT07241104RecruitingPhase 1
Study of AZD4063 for PLN R14del dilated cardiomyopathy
This trial tests a new drug called AZD4063 for people with dilated cardiomyopathy caused by a specific genetic change (PLN R14del mutation). The goal is to see if the drug can improve heart function, and it requires participants to have an ICD or CRT-D device.
AmsterdamAges 18–80 - NCT07516288RecruitingPhase 1
Second CAR-DC Cell Infusion for Advanced Heart Failure
This trial tests a second dose of specialized immune cells (called CAR-DC) in patients with severe dilated cardiomyopathy (a weakened heart muscle) who received one dose before but saw their heart function decline back to baseline. The goal is to see if a second dose is safe and can improve heart function when the first treatment's benefits wore off.
Hangzhou, Zhejiang / 浙江Ages 18–75 - NCT07293338Recruiting
Heart muscle blood flow study for dilated cardiomyopathy
This study looks at how small blood vessels in the heart affect outcomes in people with dilated cardiomyopathy (an enlarged, weak heart). You may qualify if you have heart failure with a weak pump and no significant blockages in your main heart arteries.
Hangzhou, ZhejiangAges 18 years+ - NCT07354646Recruiting
Understanding heart disease with T1 mapping MRI
This study uses a special type of MRI (T1 mapping) to better understand different heart conditions. It may help doctors improve diagnosis and treatment by looking at detailed images of your heart muscle.
Beijing, Beijing MunicipalityAges Any age - NCT07359690Recruiting
Study of Heart Muscle Biopsies
This study collects samples of heart muscle tissue (biopsy) to better understand heart conditions. It is for people who already need this biopsy for their healthcare.
Essen, North Rhine-WestphaliaAges 18 years+ - NCT02445534Recruiting
Registry for cell therapy in non-ischemic dilated heart muscle disease
This is a research registry that follows people with non-ischemic dilated cardiomyopathy (a weakened heart muscle) who are already on the right medications. It helps doctors better understand how cell-based therapy and related care affect heart function over time.
LjubljanaAges 18–65 - NCT02413450Enrolling by invitation
Using patient DNA cells to study inherited heart rhythm risks
This study uses your blood or genetic information to make “iPS cells,” lab-grown cells that can help researchers study inherited heart rhythm problems like LQTS, Brugada syndrome, CPVT, or early repolarization syndrome. It may help improve understanding of why these rhythms happen and guide future treatments.
Baltimore, MarylandAges 18–85 - NCT07345338Enrolling by invitation
Genetic testing for non-ischemic heart muscle disease
This study offers genetic testing to adults with a type of heart muscle disease (non-ischemic cardiomyopathy or dilated cardiomyopathy) that is not caused by blocked arteries. The goal is to find genetic causes, which may guide treatment and family screening.
Calgary, AlbertaAges 18 years+ - NCT07210723RecruitingPhase 2/Phase 3
Study of danicamtiv for genetic and familial dilated cardiomyopathy
This trial tests if danicamtiv can improve heart function in people with dilated cardiomyopathy caused by certain genetic changes. It may help those who have stable symptoms but still need more treatment options.
Birmingham, AlabamaAges 18 years+ - NCT07218887RecruitingPhase 1/Phase 2
Gene therapy for BAG3-related heart failure
This study tests an experimental gene therapy called ALXN2350 for people with dilated cardiomyopathy caused by a specific genetic change in the BAG3 gene. It aims to see if the therapy can improve heart function and slow disease progression.
Birmingham, AlabamaAges 18–70 - NCT06730464Recruiting
Predicting dangerous heart rhythms in non-ischemic heart disease
This study uses heart MRI scans to predict who might develop dangerous heart rhythms. It's for people with certain types of non-ischemic heart disease who have already had an MRI with contrast.
Milan, ItalyAges 18 years+ - NCT05321875RecruitingPhase 3
Candesartan to prevent heart failure in certain gene carriers
This trial tests whether candesartan (a blood-pressure medicine) can delay or prevent heart muscle weakening in people who carry a disease-causing dilated cardiomyopathy gene variant but still have fairly strong heart pumping. Participants are randomly assigned to candesartan or a placebo to see which one keeps the heart healthier over time.
Majadahonda, MadridAges 18–64 - NCT07606274RecruitingPhase 1/Phase 2
Study of NVC-001 for heart muscle disease caused by LMNA gene change
This trial tests an experimental drug called NVC-001 for people with a specific genetic heart condition (LMNA-related dilated cardiomyopathy) that causes the heart to become weak and enlarged. The goal is to see if the drug can help improve heart function.
Birmingham, AlabamaAges 18 years+
Hear when a new Dilated Cardiomyopathy (DCM) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for dilated cardiomyopathy (dcm)?
- Yes. Clin2 currently lists 29 recruiting dilated cardiomyopathy (dcm) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a dilated cardiomyopathy (dcm) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a dilated cardiomyopathy (dcm) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.